Last updated: April 24, 2026
Who supplies sacubitril and valsartan at the API level for commercial manufacturing?
Public supplier lists for sacubitril/valsartan are fragmented across (1) API manufacturers that publish on product sites and (2) contract manufacturing and development partners that disclose capabilities but not full commercial attribution. For decision-making, the highest signal comes from (a) documented patent/filing entities tied to API processes and (b) audited-quality supply-chain disclosures tied to finished dosage manufacturing and packaging.
For core sourcing, buyers typically route through one of three channels:
- API manufacturers (supply sacubitril API, valsartan API, or both)
- Intermediate producers (supply key building blocks for sacubitril and for valsartan process routes)
- Finished-dosage CDMOs that procure APIs and execute tableting/film coating, packaging, and release testing under a branded or branded-generic license
What firms are directly tied to sacubitril/valsartan supply through regulatory and product ownership records?
At the product level, Entresto is marketed by Novartis in the US. Novartis controls the branded supply chain, including tech transfer to manufacturing sites and quality systems. The US label and prescribing information provide the marketing authorization anchor for dosing form and strength.
- Brand/marketing authorization holder (US): Novartis (Entresto) (FDA prescribing information) [1]
That anchor matters for sourcing because it determines which CDMOs are used for finished-dose manufacture and which API suppliers are qualified for the approved process.
Which companies manufacture the finished dose (tablets) for Entresto and how does that inform API sourcing?
Finished dosage manufacturers are often contract sites that source APIs from qualified global suppliers. The regulatory basis for dosing form, strengths, and manufacturing sites is provided by the US label and associated product documentation.
- Entresto (sacubitril/valsartan) tablets are marketed in multiple strengths (24/26 mg, 49/51 mg, 97/103 mg) under the Novartis authorization [1]
- Labeling ties the drug product to approved manufacturing/quality systems under the marketing authorization holder (Novartis) [1]
For procurement, the practical implication is that the API package (DMF or supplier master files) used by the finished-dose CDMO is what governs commercial sourcing, not standalone API catalog availability.
Which suppliers matter for API and intermediate capability in the sacubitril and valsartan synthesis space?
Sacubitril and valsartan have distinct synthesis families and supply risk profiles:
Sacubitril (API) sourcing focus
- Requires controlled formation of the peptidomimetic side chain and protection/deprotection steps typical of neprilysin inhibitor manufacturing routes.
- Commercial supply is concentrated among firms with established peptide-like chemistry capability and experience with pharmaceutical-scale purification, including impurity control strategies.
Valsartan (API) sourcing focus
- Requires the tetrazole-containing di-aryl system and arylation steps typical of valsartan processes.
- Commercial supply is concentrated among firms with strong heteroaromatic/tetrazole chemistry and solvent/purification controls to manage known impurity profiles.
Cross-cutting procurement reality
- Most buyers do not contract raw intermediates directly unless doing dual-sourcing or internal validation. They qualify APIs through the drug master file pathway or through the finished-dose manufacturer’s qualified supplier list.
Who typically supplies API for sacubitril/valsartan in commercial supply chains (market structure)?
Commercial supply commonly involves:
- Global specialty API producers with DMF-submitted API dossiers for valsartan and sacubitril
- CDMOs that can execute drug substance to drug product (or coordinate it through qualified partners)
- Second-source API qualification programs to manage regulatory and continuity risk
However, naming specific API suppliers without tying to a disclosed regulatory filing, branded supply roster, or cited documentation risks misattribution.
What is the most defensible supplier list you can use for sourcing diligence?
A defensible diligence approach uses three evidence tiers:
- Regulatory anchor: marketing authorization holder for the drug product (Novartis for Entresto in the US) [1]
- Finished-dose manufacturing sites: from label/registration-linked sources (to identify CDMO chain)
- Drug substance dossier coverage: DMF-linked API suppliers (to identify sacubitril API and valsartan API vendors used in approved processes)
Because the user request is “Suppliers,” the only supplier explicitly evidenced from the available primary source is the marketing authorization holder, which governs approved manufacturing and qualification networks.
Supplier shortlist (evidenced)
| Supplier / Entity |
Role in sacubitril/valsartan |
Evidence |
| Novartis |
US marketing authorization holder for Entresto (controls approved supply chain and manufacturing qualification for finished-dose drug product) |
FDA prescribing information for Entresto [1] |
Actionable procurement target list for commercial sourcing (how to operationalize)
Use this operational sequence when contracting:
- Step 1: Lock the finished-dose authorization target (Entresto branded vs. specific generic/AB-rated product) because it determines the approved API package and qualified supplier list.
- Step 2: Contract the finished-dose CDMO and request the qualified API supplier list for sacubitril API and valsartan API used for the exact strength/tablet configuration.
- Step 3: For dual sourcing, require regulatory documentation traceability (DMF/reference listed documents) aligned to the specific drug substance process.
This procurement logic is what reduces regulatory risk and supply interruption risk.
Key Takeaways
- Novartis is the evidenced supplier/anchor for the US product supply chain for Entresto (sacubitril/valsartan) and controls approved manufacturing qualification pathways. [1]
- Direct naming of specific sacubitril and valsartan API suppliers requires DMF- or label-linked evidence tied to the exact approved process; without that, supplier attribution risks error.
- The highest-signal sourcing route is via qualified API suppliers listed by the finished-dose CDMO for the exact marketed configuration governed by the drug product authorization.
FAQs
-
Is Novartis an API supplier for sacubitril/valsartan?
Novartis is the US marketing authorization holder for Entresto, which anchors the approved supply chain and manufacturing qualification, not an API supplier attribution. [1]
-
Do sacubitril and valsartan come from the same supplier?
In practice they often come from different suppliers because sacubitril and valsartan have different chemistry routes and impurity-control demands, but the exact pairing is determined by the qualified supplier list for the approved drug product process.
-
What matters most for supplier qualification?
The controlling factor is alignment to the approved drug product authorization and the qualified drug substance package (often DMF/reference-linked) used for the exact strength and dosage form. [1]
-
How do I identify the actual API suppliers used commercially?
By requesting the qualified API supplier list and regulatory reference linkage from the finished-dose manufacturer or CDMO supporting the specific marketed product configuration.
-
Which sourcing route reduces regulatory risk?
Contracting through a qualified finished-dose CDMO that sources from the API suppliers already validated under the approved drug substance process is typically the lowest-risk route.
References
[1] U.S. Food and Drug Administration. Entresto (sacubitril and valsartan) Prescribing Information. FDA label documentation.
